# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes a systematic review evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.relatedArtifact[].display
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.relatedArtifact[].document.title
Acupuncture for the prevention of episodic migraine

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a positive outcome when using the treatment as a preventive measure against the disease.

# entry[].resource.title
This Evidence resource describes a clinical study evaluating diacerein-based treatment for knee osteoarthritis.

# entry[].resource.relatedArtifact[].display
Zhiyu Wang et al. American Journal of Translational Research, 01 / 2023

# entry[].resource.relatedArtifact[].document.title
Diacerein plus glucosamine hydrochloride improves the safety and efficacy and inhibit inflammatory factors in the treatment of knee osteoarthritis

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This resource is about citalopran for depression.

# entry[].resource.relatedArtifact[].display
Madhukar H. Trivedi et al. American Journal of Psychiatry (American Psychiatric Association Publishing), 01 / 2006

# entry[].resource.relatedArtifact[].document.title
Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes the efficacy of placebo, from a systematic review evaluating acupuncture for the prevention of episodic migraine.

# entry[].resource.relatedArtifact[].display
Klaus Linde et al. Cochrane Database of Systematic Reviews, 06 / 2016

# entry[].resource.relatedArtifact[].document.title
Acupuncture for the prevention of episodic migraine

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a positive outcome when using the placebo as a preventive measure against the disease.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This resource describes the efficacy of OnabotulinumtoxinA for episodic migraine, measuring temporary reduction of symptoms.

# entry[].resource.relatedArtifact[].display
Patricia Pozo-Rosich et al. Cephalalgia (SAGE Publications), 10 / 2025

# entry[].resource.relatedArtifact[].document.title
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who experienced a temporary reduction in symptoms with the use of a given treatment, regardless of the extent of that reduction.

# entry[].resource.title
This resource describes the efficacy of OnabotulinumtoxinA for episodic migraine, measuring temporary reduction of symptoms.

# entry[].resource.relatedArtifact[].display
Patricia Pozo-Rosich et al. Cephalalgia (SAGE Publications), 10 / 2025

# entry[].resource.relatedArtifact[].document.title
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who experienced a temporary reduction in symptoms with the use of a given treatment, regardless of the extent of that reduction.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This resource describes the efficacy of OnabotulinumtoxinA for episodic migraine, measuring temporary reduction of symptoms.

# entry[].resource.relatedArtifact[].display
Patricia Pozo-Rosich et al. Cephalalgia (SAGE Publications), 10 / 2025

# entry[].resource.relatedArtifact[].document.title
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This resource describes the efficacy of OnabotulinumtoxinA for episodic migraine, measuring temporary reduction of symptoms.

# entry[].resource.relatedArtifact[].display
Patricia Pozo-Rosich et al. Cephalalgia (SAGE Publications), 10 / 2025

# entry[].resource.relatedArtifact[].document.title
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This resource describes the efficacy of OnabotulinumtoxinA for episodic migraine, measuring temporary reduction of symptoms.

# entry[].resource.relatedArtifact[].display
Patricia Pozo-Rosich et al. Cephalalgia (SAGE Publications), 10 / 2025

# entry[].resource.relatedArtifact[].document.title
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.

# entry[].resource.title
This Evidence resource describes an open-label clinical study evaluating olmesartan medoxomil-based treatment for hypertension.

# entry[].resource.relatedArtifact[].display
Joel M. Neutel et al. The Journal of Clinical Hypertension (Wiley), 04 / 2004

# entry[].resource.relatedArtifact[].document.title
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control

# entry[].resource.variableDefinition[].description
Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.

# entry[].resource.statistic[].description
Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.